| The Bottom Line |
| |
Article Title |
Author(s) |
Pages |
|
|
|
New Hope for Mobilization Failures . . . Again
21 December 2011
Patients undergoing peripheral blood stem cell mobilization for autologous transplantation may fail to achieve the generally accepted minimum threshold for transplantation (≥2 × 106 CD34/kg) despite u...
|
John F. DiPersio
|
159-160
|
|
|
|
My AML Cytogenetics Classification Scheme Is Better Than Yours
08 December 2011
Growing up in Rhode Island, my brother and I spent hours – I mean, hours – in the schoolyard around the block from our house arguing over which baseball team was better: the Yankees or the Red Sox. I ...
|
Mikkael A. Sekeres
|
160-161
|
|
| Reports |
| |
Article Title |
Author(s) |
Pages |
|
|
|
NCI, NHLBI/PBMTC First International Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: Health-Related Quality of Life, Functional, and Neurocognitive Outcomes
12 December 2011
The purpose of this manuscript is to summarize issues relevant to health-related quality of life (HRQL), physical function, and neurocognitive function for survivors of pediatric hematopoietic stem ce...
|
Susan K. Parsons,
Sean Phipps,
Lillian Sung,
K. Scott Baker,
Michael A. Pulsipher,
Kirsten K. Ness
et al.
|
162-171
|
|
|
|
The National Marrow Donor Program’s Symposium on Hematopoietic Cell Transplantation in 2020: A Health Care Resource and Infrastructure Assessment
16 December 2011
Hematopoietic cell transplantation (HCT) is the only known curative therapy for many patients with life-threatening hematologic and oncologic diseases. It is estimated that the National Marrow Donor P...
|
Navneet S. Majhail,
Elizabeth A. Murphy,
Ellen M. Denzen,
Stacy S. Ferguson,
Claudio Anasetti,
Arthur Bracey,
Linda Burns,
Richard Champlin,
Norman Hubbard,
Miriam Markowitz,
Richard T. Maziarz,
Erin Medoff,
Joyce Neumann,
Kim Schmit-Pokorny,
Daniel J. Weisdorf,
Deborah S. Yolin Raley,
Jeffrey Chell,
Edward L. Snyder
et al.
|
172-182
|
|
| Review |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Easy-to-Read Informed Consent Forms for Hematopoietic Cell Transplantation Clinical Trials
01 August 2011
Informed consent is essential to ethical research and is requisite to participation in clinical research. Yet most hematopoietic cell transplantation (HCT) informed consent forms (ICFs) are written at...
|
Ellen M. Denzen,
Martha E. Burton Santibáñez,
Heather Moore,
Amy Foley,
Iris D. Gersten,
Cathy Gurgol,
Navneet S. Majhail,
Ryan Spellecy,
Mary M. Horowitz,
Elizabeth A. Murphy
et al.
|
183-189
|
|
| Biology |
| |
Article Title |
Author(s) |
Pages |
|
|
|
The Pretransplantation Serum Cytokine Profile in Allogeneic Stem Cell Recipients Differs from Healthy Individuals, and Various Profiles are Associated with Different Risks of Posttransplantation Complications
21 October 2011
Cytokines play a key role in regulation of normal and malignant hematopoiesis, angiogenesis, and inflammation. Serum levels of several cytokines are altered in patients with hematologic malignancies, ...
|
Håkon Reikvam,
Knut Anders Mosevoll,
Guro Kristin Melve,
Clara-Cecilie Günther,
Malvin Sjo,
Pål-Tore Bentsen,
Øystein Bruserud
et al.
|
190-199
|
|
|
|
T Cell and B Cell Immunity can be Reconstituted with Mismatched Hematopoietic Stem Cell Transplantation Without Alkylator Therapy in Artemis-Deficient Mice Using Anti-Natural Killer Cell Antibody and Photochemically Treated Sensitized Donor T Cells
19 October 2011
Children with Artemis-deficient T−B−NK+ severe combined immunodeficiency are at high risk for graft rejection from natural killer (NK) cells and toxicity from increased sensitivity to the alkylating a...
|
Tony Z. Xiao,
Kanal Singh,
Elizabeth Dunn,
Rageshree Ramachandran,
Morton J. Cowan
et al.
|
200-209
|
|
|
|
Identification of a Coordinated CD8 and CD4 T Cell Response Directed Against Mismatched HLA Class I Causing Severe Acute Graft-versus-Host Disease
19 October 2011
After HLA class I-mismatched stem cell transplantation, allo-HLA–directed CD8 T cell responses can be activated without the help of CD4 T cells if memory CD8 T cells cross-reactive against the allo-HL...
|
Avital L. Amir,
Renate S. Hagedoorn,
Simone A.P. van Luxemburg-Heijs,
Erik W.A. Marijt,
Alwine B. Kruisselbrink,
J.H. Frederik Falkenburg,
Mirjam H.M. Heemskerk
et al.
|
210-219
|
|
| Clinical Research |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Limiting the Daily Total Nucleated Cell Dose of Cryopreserved Peripheral Blood Stem Cell Products for Autologous Transplantation Improves Infusion-Related Safety with No Adverse Impact on Hematopoietic Engraftment
16 June 2011
Cryopreserved peripheral blood stem cell (PBSC) products can induce a number of infusion-related adverse reactions, including life-threatening cardiac, neurologic, and other end-organ complications. P...
|
Nandita Khera,
Jack Jinneman,
Barry E. Storer,
Shelly Heimfeld,
Megan M. O’Meara,
Thomas R. Chauncey,
Stephanie J. Lee,
Michael Linenberger
et al.
|
220-228
|
|
|
|
Effect of Early Posttransplantation Tacrolimus Concentration on the Development of Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation from Unrelated Donors
27 June 2011
Only limited data are available regarding the relationship between blood concentration of tacrolimus and its efficacy in preventing acute graft-versus-host disease (aGVHD). We retrospectively evaluate...
|
Takehiko Mori,
Jun Kato,
Takayuki Shimizu,
Yoshinobu Aisa,
Tomonori Nakazato,
Akiko Yamane,
Yukako Ono,
Hiroyoshi Kunimoto,
Shinichiro Okamoto
et al.
|
229-234
|
|
|
|
EBMT Risk Score Predicts Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Who Have Failed a Previous Transplantation Procedure
01 July 2011
Increasing numbers of allogeneic hematopoietic stem cell transplantation (allo-SCT) are being performed for patients who have failed a previous allogeneic or autologous SCT. We investigated whether th...
|
Katayoun Rezvani,
Edward J. Kanfer,
David Marin,
Ian Gabriel,
Amin Rahemtulla,
Alexandra Taylor,
Donald MacDonald,
Francesco Dazzi,
Dragana Milojkovic,
Letizia Foroni,
Jiri Pavlu,
Jeremy Sargent,
Rifca Le Dieu,
John M. Goldman,
Jane Apperley,
Richard Szydlo
et al.
|
235-240
|
|
|
|
Plerixafor Added to Chemotherapy Plus G-CSF Is Safe and Allows Adequate PBSC Collection in Predicted Poor Mobilizer Patients with Multiple Myeloma or Lymphoma
26 July 2011
We evaluated the safety and efficacy of plerixafor, subsequent to disease-specific chemotherapy followed by granulocyte-colony stimulating factor (G-CSF), in 37 multiple myeloma (MM) or lymphoma patie...
|
Immacolata Attolico,
Vincenzo Pavone,
Angelo Ostuni,
Bernardo Rossini,
Maurizio Musso,
Alessandra Crescimanno,
Massimo Martino,
Pasquale Iacopino,
Giuseppe Milone,
Patrizia Tedeschi,
Sabrina Coluzzi,
Roberta Nuccorini,
Sara Pascale,
Elvira Di Nardo,
Attilio Olivieri
et al.
|
241-249
|
|
|
|
Double Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Study from the SFGM-TC
11 July 2011
The purpose of this paper is to describe the outcome of patients who underwent double allogeneic hematopoietic stem cell transplantation (AHSCT) with reduced-intensity conditioning regimens (RIC). For...
|
J.O. Bay,
A. Cabrespine,
C. Faucher,
R. Tabrizi,
P. Bordigoni,
A. Berceanu,
V. Coiteux,
M. Renaud,
V. Mialou,
M. Robin,
M. Kuentz,
P. Chevallier,
N. Dhédin,
A. Huynh,
F. Garban,
F. Witz,
A. Buzyn,
T. De Revel,
C. Galambrun,
E. Deconinck,
N. Contentin,
S. François,
N. Gratecos,
D. Blaise,
M. Michallet,
Société Française de Greffe de Moelle et de Thérapie Cellulaire
et al.
|
250-256
|
|
|
|
Idiotype Immunization Following High-Dose Therapy and Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma
06 July 2011
The treatment of low- and intermediate-grade subtypes of malignant lymphoma continues to evolve. Mantle cell lymphoma (MCL) accounts for 6% of all non-Hodgkin lymphoma (NHL) and is generally considere...
|
Peter R. Holman,
Caitlin Costello,
Margarida deMagalhaes-Silverman,
Sue Corringham,
Januario Castro,
Edward D. Ball
et al.
|
257-264
|
|
|
|
Accurate Targeting of Daily Intravenous Busulfan with 8-Hour Blood Sampling in Hospitalized Adult Hematopoietic Cell Transplant Recipients
06 July 2011
Daily intravenous (i.v.) busulfan is increasingly being used in hematopoietic cell transplantation (HCT) conditioning regimens. Intravenous busulfan doses administered at the traditional frequency of ...
|
Rosa F. Yeh,
Matthew A. Pawlikowski,
David K. Blough,
George B. McDonald,
Paul V. O’Donnell,
Andrew Rezvani,
H. Joachim Deeg,
Jeannine S. McCune
et al.
|
265-272
|
|
|
|
Genetic Variations in the Mycophenolate Mofetil Target Enzyme Are Associated with Acute GVHD Risk after Related and Unrelated Hematopoietic Cell Transplantation
11 July 2011
Inosine monophosphate dehydrogenase (IMPDH) is the target enzyme of mycophenolate mofetil (MMF). Single nucleotide polymorphisms (SNPs) in the IMPDH1 gene are reportedly relevant to acute rejection in...
|
Weijie Cao,
Haowen Xiao,
Xiaoyu Lai,
Yi Luo,
Jimin Shi,
Yamin Tan,
Weiyan Zheng,
Jingsong He,
Wanzhuo Xie,
Li Li,
Xiujin Ye,
Xiaohong Yu,
Maofang Lin,
Zhen Cai,
He Huang
et al.
|
273-279
|
|
|
|
Classifying Cytogenetics in Patients with Acute Myelogenous Leukemia in Complete Remission Undergoing Allogeneic Transplantation: A Center for International Blood and Marrow Transplant Research Study
02 August 2011
Cytogenetics play a major role in determining the prognosis of patients with acute myelogenous leukemia (AML). However, existing cytogenetics classifications were developed in chemotherapy-treated pat...
|
Philippe Armand,
Haesook T. Kim,
Mei-Jie Zhang,
Waleska S. Perez,
Paola S. Dal Cin,
Thomas R. Klumpp,
Edmund K. Waller,
Mark R. Litzow,
Jane L. Liesveld,
Hillard M. Lazarus,
Andrew S. Artz,
Vikas Gupta,
Bipin N. Savani,
Philip L. McCarthy,
Jean-Yves Cahn,
Harry C. Schouten,
Jürgen Finke,
Edward D. Ball,
Mahmoud D. Aljurf,
Corey S. Cutler,
Jacob M. Rowe,
Joseph H. Antin,
Luis M. Isola,
Paolo Di Bartolomeo,
Bruce M. Camitta,
Alan M. Miller,
Mitchell S. Cairo,
Keith Stockerl-Goldstein,
Jorge Sierra,
M. Lynn Savoie,
Joerg Halter,
Patrick J. Stiff,
Chadi Nabhan,
Ann A. Jakubowski,
Donald W. Bunjes,
Effie W. Petersdorf,
Steven M. Devine,
Richard T. Maziarz,
Martin Bornhauser,
Victor A. Lewis,
David I. Marks,
Christopher N. Bredeson,
Robert J. Soiffer,
Daniel J. Weisdorf
et al.
|
280-288
|
|
|
|
Reduced-Intensity Conditioning before Allogeneic Hematopoietic Stem Cell Transplantation in Patients Over 60 Years: A Report from the SFGM-TC
21 July 2011
This retrospective multicenter report assessed the outcome of 600 patients with hematologic diseases older than 60 years who received reduced-intensity conditioning (RIC) allogeneic hematopoietic stem...
|
Patrice Chevallier,
Richard M. Szydlo,
Didier Blaise,
Reza Tabrizi,
Mauricette Michallet,
Madalina Uzunov,
Nathalie Fegueux,
François Guilhot,
Simona Lapusan,
Nicole Gratecos,
Jean-Yves Cahn,
Gerard Socié,
Ibrahim Yakoub-Agha,
Anne Huynh,
Sylvie Francois,
Jacques-Olivier Bay,
Sébastien Maury,
Agnes Buzyn,
Nathalie Contentin,
Mohamad Mohty
et al.
|
289-294
|
|
|
|
Development and Validation of a Test Dose Strategy for Once-Daily i.v. Busulfan: Importance of Fixed Infusion Rate Dosing
28 July 2011
Intravenous (i.v.) busulfan (Bu) administered once daily in myeloablative transplant regimens is convenient, effective, and relatively well tolerated. Therapeutic drug monitoring is recommended as non...
|
S. Bill Kangarloo,
Farrukh Naveed,
Ella S.M. Ng,
M. Ahsan Chaudhry,
Judy Wu,
Nizar J. Bahlis,
Christopher B. Brown,
Andrew Daly,
Peter Duggan,
Michelle Geddes,
Diana Quinlan,
Mary Lynn Savoie,
Mona Shafey,
Douglas A. Stewart,
Jan Storek,
Maggie Yang,
Nancy Zacarias,
Ping Yue,
Anthony M. Magliocco,
James A. Russell
et al.
|
295-301
|
|
|
|
Allogeneic Hematopoietic Cell Transplantation for Chronic Myelofibrosis in Australia and New Zealand: Older Recipients Receiving Myeloablative Conditioning at Increased Mortality Risk
12 May 2011
This retrospective registry analysis examined predictive factors for outcome in 57 patients who underwent allogeneic or syngeneic hematopoietic cell transplantation (HCT) for chronic myelofibrosis (CM...
|
Ian Nivison-Smith,
Anthony J. Dodds,
Jason Butler,
Kenneth F. Bradstock,
David D.F. Ma,
Judy M. Simpson,
Jeff Szer
et al.
|
302-308
|
|
| Brief Articles |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Stable Long-Term Pulmonary Function after Myeloablative Double Cord Blood Transplant
16 August 2011
Pulmonary dysfunction has been well described after myeloablative transplantation with conventional allogeneic donors; however, whether the risk is similar after alternative donor transplantation with...
|
Filippo Milano,
Jason W. Chien,
Ivy Riffkin,
Jonathan A. Gutman,
Laura Newell,
Steven A. Pergam,
Colleen Delaney
et al.
|
309-313
|
|
|
|
Plerixafor for Autologous Peripheral Blood Stem Cell Mobilization in Patients Previously Treated with Fludarabine or Lenalidomide
14 October 2011
Fludarabine and lenalidomide are essential drugs in the front-line treatment of non-Hodgkin lymphoma (NHL) and multiple myeloma (MM), respectively. Data suggests that fludarabine and lenalidomide ther...
|
Florent Malard,
Nicolaus Kröger,
Ian H. Gabriel,
Kai Hübel,
Jane F. Apperley,
Grzegorz W. Basak,
Kenneth W. Douglas,
Catarina Geraldes,
Ozren Jaksic,
Zdenek Koristek,
Francesco Lanza,
Roberto Lemoli,
Gabor Mikala,
Dominik Selleslag,
Nina Worel,
Mohamad Mohty,
Rafael F. Duarte
et al.
|
314-317
|
|
|
|
Dasatinib as Salvage Therapy for Steroid Refractory and Imatinib Resistant or Intolerant Sclerotic Chronic Graft-versus-Host Disease
07 November 2011
Sclerotic chronic graft-versus-host disease (scGVHD) is a severe form of this disease that resembles systemic sclerosis and has limited and disappointing treatment options. Tyrosine kinase inhibitors ...
|
Isabel Sánchez-Ortega,
Octavio Servitje,
Montserrat Arnan,
Guillermo Ortí,
Teresa Peralta,
Federico Manresa,
Rafael F. Duarte
et al.
|
318-323
|
|
|
|
A Phase I Study of Gemtuzumab Ozogamicin (GO) in Combination with Busulfan and Cyclophosphamide (Bu/Cy) and Allogeneic Stem Cell Transplantation in Children with Poor-Risk CD33+ AML: A New Targeted Immunochemotherapy Myeloablative Conditioning (MAC) Regimen
10 November 2011
Children with high-risk acute myelogenous leukemia (AML) (induction failure [IF], refractory relapse [RR], third complete remission [CR3]) have dismal outcomes. Over 80% of AML patients express CD33, ...
|
Prakash Satwani,
Monica Bhatia,
James H. Garvin,
Diane George,
Filemon Dela Cruz,
John Le Gall,
Zhezhen Jin,
Joseph Schwartz,
Deirdre Duffy,
Carmella van de Ven,
Sandra Foley,
Ria Hawks,
Erin Morris,
Lee Ann Baxter-Lowe,
Mitchell S. Cairo
et al.
|
324-329
|
|
| ASBMT News |
| |
Article Title |
Author(s) |
Pages |
|
|
|
2012 BMT Tandem Meetings
16 December 2011
2012 BMT TANDEM MEETINGS WILL BE FEB. 1-5 IN SAN DIEGO
|
|
330
|
|
| Frontmatter |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Purpose and Scope
|
|
A1
|
|
|
|
Editorial Board
|
|
A2
|
|
|
|
Officers and Directors of ASBMT
|
|
A3
|
|
|
|
Contents
|
|
A5-A8
|
|
